Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing | In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the issues that have tripped the company up in recent years, alongside the strengths that could help carry it forward.
CEO Garijo posts Q2 beat (+8%, Dupixent +38% to €5.2B) but must diversify as blockbuster faces biosimilar risk post-2031. Restructuring signals Sanofi is de-risking single-asset dependency—key test of pharma portfolio strategy and R&D innovation governance.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise